A study is examining the risk of secondary malignancy in patients with chronic lymphocytic leukemia (CLL) who are receiving targeted therapy. However, reports on the study's specifics are unclear, with some outlets discussing unrelated topics such as cancer risk in patients with HIV, stroke, or systemic lupus erythematosus. The focus of the study appears to be on secondary malignancies, but the exact scope and findings are uncertain.